SHANGHAI, March 4, 2016 /PRNewswire/ -- WuXi AppTec Co. Ltd. (WuXi), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that its small-molecule process development and manufacturing subsidiary Shanghai SynTheAll Pharmaceutical Co., Ltd. (STA) began operations at a new, fully integrated R&D and cGMP manufacturing site in Changzhou in February 2016.
The new campus is being constructed in phases. The administration building, R&D building, one large-scale manufacturing plant, and supporting units are now operating, with construction to continue on other buildings. Upon completion, the site will employ more than 500 scientists and will add more than 1,000 m3 of reactor volume, doubling STA's existing R&D capacity and quadrupling its manufacturing capacity. Besides adding capacity, this state-of-the-art integrated campus will provide a unique one-site solution for STA customers to advance their active pharmaceutical ingredients (APIs) and advanced intermediates through preclinical and clinical development to global commercial launch.
"The new site in Changzhou brings our customers added capacity, greater flexibility, and the unsurpassed quality of WuXi's operations," said Dr. Minzhang Chen, CEO of STA. "It further strengthens STA's position as a world-leading CDMO, offering a truly unique integrated solution to our global partners."
"We are pleased to open our new Changzhou site, which greatly expands our small-molecule process development and manufacturing services," said Dr. Ge Li, Chairman and CEO of WuXi AppTec. "This new facility further strengthens WuXi's comprehensive, integrated open-access platform of R&D services to serve our global customers."
About WuXi AppTec
WuXi AppTec is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services throughout the drug and medical device R&D process. WuXi AppTec is also building a platform to provide clinical diagnostic services directly to physicians and their patients globally. WuXi AppTec's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. Please visit: http://www.wuxiapptec.com.
For more information, please contact:
Director, Corporate Communications